Expression of TRAIL, DR4, and DR5 in Bladder Cancer: Correlation With Response to Adjuvant Therapy and Implications of Prognosis

The results of the present study have shown for the first time that a combination of DR4 and DR5 expression have significant value in predicting the prognosis of bladder cancer. In addition, patients with high expression of both DR4 and DR5 might benefit from epirubicin therapy.